J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 8, Number 10, October 2016, pages 743-748

Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study)

Figure 1. Time course of systolic blood pressure (SBP) and diastolic BP (DBP) during the study period in the azilsartan and olmesartan groups. *P < 0.05 vs. at baseline in the azilsartan group. #P < 0.05 vs. at 12 weeks in the olmesartan group.

Figure 2. Percentages of patients who reached the target blood pressure (< 130/80 mm Hg) at 0 and 12 weeks in the azilsartan and olmesartan groups. *P < 0.05 vs. at 0 weeks in the azilsartan group. #P < 0.05 vs. at 0 weeks in the olmesartan group.

Figure 3. Blood concentrations of anti-inflammation and inflammation markers such as adiponectin (A), pentraxin-3 (PTX-3) (B) and high-sensitive C-reactive protein (hs-CRP) (C). N.S., not significant.

**Table 1.** Patient Characteristic at Baseline in the Azilsartan and Olmesartan Groups
	Azilsartan group (n = 18)	Olmesartan group (n = 20)	P value (azilsartan vs. olmesartan)
BMI: body mass index; WC: waist circumference; MetS: metabolic syndrome; DM: diabetes mellitus; DL: dyslipidemia; HU: hyperuricemia; SBP: systolic blood pressure; DBP: diastolic BP; PR: pulse rate; LVEF: left ventricular ejection fraction; CCB: calcium channel blocker; SU: sulfonylurea; DPP4-I: dipeptidyl peptidase-4 inhibitor.
Age (years)	68 ± 7	71 ± 9	0.24
Male (%)	78	65	0.40
BMI (kg/m²)	26.1 ± 2.7	26.0 ± 3.7	0.98
WC (cm)	94 ± 7	90 ± 11	0.18
MetS (%)	89	65	0.09
Smoking (%)	72	50	0.17
DM (%)	50	55	0.76
DL (%)	94	95	0.94
HU (%)	17	30	0.35
SBP (mm Hg)	128 ± 17	129 ± 11	0.99
DBP (mm Hg)	71 ± 14	70 ± 12	0.93
PR (/min)	67 ± 10	72 ± 11	0.18
LVEF (%)	63 ± 11	62 ± 9	0.88
Medication
β-blocker (%)	44	20	0.11
α-blocker (%)	28	10	0.17
CCB (%)	50	70	0.22
Diuretics (%)	0	20	0.046
Statin (%)	89	80	0.47
Nicorandil (%)	22	10	0.32
SU (%)	6	5	0.94
Metformin (%)	6	20	0.20
DPP4-I (%)	39	40	0.95
Insulin (%)	22	15	0.35

Table 1. Patient Characteristic at Baseline in the Azilsartan and Olmesartan Groups

Azilsartan group (n = 18)

Olmesartan group (n = 20)

P value (azilsartan vs. olmesartan)

BMI: body mass index; WC: waist circumference; MetS: metabolic syndrome; DM: diabetes mellitus; DL: dyslipidemia; HU: hyperuricemia; SBP: systolic blood pressure; DBP: diastolic BP; PR: pulse rate; LVEF: left ventricular ejection fraction; CCB: calcium channel blocker; SU: sulfonylurea; DPP4-I: dipeptidyl peptidase-4 inhibitor.

Age (years)

68 ± 7

71 ± 9

0.24

Male (%)

0.40

BMI (kg/m²)

26.1 ± 2.7

26.0 ± 3.7

0.98

WC (cm)

94 ± 7

90 ± 11

0.18

MetS (%)

0.09

Smoking (%)

0.17

DM (%)

0.76

DL (%)

0.94

HU (%)

0.35

SBP (mm Hg)

128 ± 17

129 ± 11

0.99

DBP (mm Hg)

71 ± 14

70 ± 12

0.93

PR (/min)

67 ± 10

72 ± 11

0.18

LVEF (%)

63 ± 11

62 ± 9

0.88

Medication

β-blocker (%)

0.11

α-blocker (%)

0.17

CCB (%)

0.22

Diuretics (%)

0.046

Statin (%)

0.47

Nicorandil (%)

0.32

SU (%)

0.94

Metformin (%)

0.20

DPP4-I (%)

0.95

Insulin (%)

0.35

**Table 2.** The Biochemical Parameters in Blood at 0 and 12 Weeks in the Azilsartan and Olmesartan Groups
	Azilsartan group (n = 18)	Olmesartan group (n = 20)
UN: urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; Na: sodium; K: potassium; Cl: chloride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; CK: creatinine kinase; Glu: glucose; HbA1c: hemoglobin A1c; NT-proBNP: N-terminal pro-brain natriuretic peptide.
UN, mg/dL	17 ± 5	18 ± 5	0.38	19 ± 6	20 ± 9	0.50
Cr, mg/dL	0.9 ± 0.2	1.0 ± 0.2	0.009	1.0 ± 0.3	1.0 ± 0.2	0.08
eGFR, mL/min/1.73 m²	63 ± 13	58 ± 12	0.003	58 ± 17	55 ± 15	0.55
UA, mg/dL	5.5 ± 1.1	5.7 ± 0.8	0.67	5.2 ± 1.1	5.9 ± 1.6	0.17
Na, mEq/L	142 ± 2	142 ± 2	0.67	141 ± 3	142 ± 3	0.64
K, mEq/L	4.3 ± 0.4	4.5 ± 0.5	0.07	4.3 ± 0.4	4.5 ± 0.4	0.30
Cl, mEq/L	105 ± 3	106 ± 3	0.12	106 ± 4	106 ± 4	0.70
LDL-C, mg/dL	85 ± 27	87 ± 38	0.70	76 ± 28	77 ± 23	0.86
HDL-C, mg/dL	47 ± 15	47 ± 12	0.80	43 ± 13	45 ± 15	0.10
TG, mg/dL	150 ± 71	144 ± 58	0.70	144 ± 86	139 ± 82	0.69
TC, mg/dL	160 ± 23	166 ± 42	0.55	146 ± 33	148 ± 30	0.64
AST, IU/L	27 ± 7	27 ± 7	0.96	27 ± 14	26 ± 12	0.60
ALT, IU/L	26 ± 9	27 ± 12	0.72	26 ± 14	24 ± 10	0.15
LDH, IU/L	202 ± 36	195 ± 28	0.39	197 ± 35	186 ± 31	0.08
CK, IU/L	132 ± 79	128 ± 58	0.80	117 ± 73	116 ± 68	0.97
Glu, mg/dL	115 ± 30	124 ± 60	0.56	121 ± 30	126 ± 38	0.51
HbA1c, %	6.6 ± 1.0	6.8 ± 1.3	0.22	7.0 ± 1.7	6.7 ± 1.5	0.36
NT-proBNP, pg/mL	114 ± 96	111 ± 104	0.90	324 ± 504	203 ± 258	0.07

Table 2. The Biochemical Parameters in Blood at 0 and 12 Weeks in the Azilsartan and Olmesartan Groups

Azilsartan group (n = 18)

Olmesartan group (n = 20)

0 weeks

12 weeks

P value (0 vs. 12 weeks)

0 weeks

12 weeks

P value (0 vs. 12 weeks)

UN: urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; Na: sodium; K: potassium; Cl: chloride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; CK: creatinine kinase; Glu: glucose; HbA1c: hemoglobin A1c; NT-proBNP: N-terminal pro-brain natriuretic peptide.

UN, mg/dL

17 ± 5

18 ± 5

0.38

19 ± 6

20 ± 9

0.50

Cr, mg/dL

0.9 ± 0.2

1.0 ± 0.2

0.009

1.0 ± 0.3

1.0 ± 0.2

0.08

eGFR, mL/min/1.73 m²

63 ± 13

58 ± 12

0.003

58 ± 17

55 ± 15

0.55

UA, mg/dL

5.5 ± 1.1

5.7 ± 0.8

0.67

5.2 ± 1.1

5.9 ± 1.6

0.17

Na, mEq/L

142 ± 2

0.67

141 ± 3

142 ± 3

0.64

K, mEq/L

4.3 ± 0.4

4.5 ± 0.5

0.07

4.3 ± 0.4

4.5 ± 0.4

0.30

Cl, mEq/L

105 ± 3

106 ± 3

0.12

106 ± 4

0.70

LDL-C, mg/dL

85 ± 27

87 ± 38

0.70

76 ± 28

77 ± 23

0.86

HDL-C, mg/dL

47 ± 15

47 ± 12

0.80

43 ± 13

45 ± 15

0.10

TG, mg/dL

150 ± 71

144 ± 58

0.70

144 ± 86

139 ± 82

0.69

TC, mg/dL

160 ± 23

166 ± 42

0.55

146 ± 33

148 ± 30

0.64

AST, IU/L

27 ± 7

0.96

27 ± 14

26 ± 12

0.60

ALT, IU/L

26 ± 9

27 ± 12

0.72

26 ± 14

24 ± 10

0.15

LDH, IU/L

202 ± 36

195 ± 28

0.39

197 ± 35

186 ± 31

0.08

CK, IU/L

132 ± 79

128 ± 58

0.80

117 ± 73

116 ± 68

0.97

Glu, mg/dL

115 ± 30

124 ± 60

0.56

121 ± 30

126 ± 38

0.51

HbA1c, %

6.6 ± 1.0

6.8 ± 1.3

0.22

7.0 ± 1.7

6.7 ± 1.5

0.36

NT-proBNP, pg/mL

114 ± 96

111 ± 104

0.90

324 ± 504

203 ± 258

0.07